Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of CHOP-rituximab with early Zevalin consolidation in untreated elderly CD20-positive diffuse large B-cell lymphoma
2006-006179-19Phase 2Active
- Sponsor
- Centre Antoine Lacassagne
- Start
- Feb 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan and rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by Centre Antoine Lacassagne. Primary endpoint: Event-free survival. Started Feb 2007; status: active.
02
Drugs
ibritumomab tiuxetanrituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2006-006179-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006179-19.